U.S. experiment uses AIDS to fight AIDS: Knowledge Driven Revolution

An AIDS virus genetically engineered to fight other AIDS viruses worked better than expected, suppressing the virus and renewing the immune systems of a few patients, researchers reported on Monday.

The study involved just five people, and such an approach needs years more study, they cautioned -- but the surprising results offer new hope both for the field of gene therapy and for treating the fatal and incurable AIDS virus.

"The goal of this phase I trial was safety and feasibility and the results established that," said Dr. Carl June of the University of Pennsylvania School of Medicine, who led the study.

"But the results also hint at something much more," he added.

"It seemed to have a vaccine-like effect in that the immune system was better in most of the patients than when they enrolled. We are trying to study the mechanism."

The AIDS virus infects close to 40 million people worldwide and has killed 25 million. A cocktail of drugs can help control infection, but there is no cure and no vaccine.

The drugs cause sometimes severe side-effects in some patients and the virus can evolve resistance, so that patients have to move to new drug combinations.

Gene therapy is a promising but troubled field of research based on the premise that altering genes can cure disease. It has cured only a few patients, and some have developed leukemia as a consequence. One gene therapy volunteer died in 1999.

June's team tried a new gene therapy approach, first crippling the HIV virus, they report in this week's issue of the Proceedings of the National Academy of Sciences.

"The virus is gutted so that it only has half the size of the original or pathogenic virus," June said in a telephone interview.

ANTISENSE APPROACH

The so-called envelope gene remains, and is reversed, a manipulation called antisense.

The researchers then recruited five patients with HIV who were beginning to fail treatment, meaning the drugs no longer worked and the virus was beginning to damage their immune systems.

June's team removed the immune cells, CD4 T-cells, that are attacked by HIV. The researchers infected the CD4 cells in the lab with their newly engineered antisense HIV virus, then infused them back onto the patients.

When HIV or any other virus infects a cell, it injects its own genetic material into the cell. The cell is turned into a virus factory, sometimes pumping out thousands of copies of a virus before it explodes.

After the new antisense virus was infused, newly infected cells pumped out defective virus, June said.

"The virus particles that are released are, like, sterile. They are nonpathogenic," June said.

This test was meant only to show that the approach was safe, and three years later, none of the patients show any ill effects.

The treatment appears to have helped restore the immune systems of four of the five patients, and the virus remains partly suppressed.

"We put back more (CD4 cells) than we took out. We don't know if that is why their immune system gets better, because there are more soldiers, or whether it got better because of better antiviral effects," June said.

The therapy is being developed by Gaithersburg, Maryland-based VIRxSYS Corp. and the studies are partly paid for by the National Institute of Allergy and Infectious Diseases.

Phase II trials are underway in HIV patients who have disease well-controlled by drugs. June said it is not yet clear if the treatment could work only in infected patients, or might even be used as a preventive vaccine some day.

Read Today's Knowledge Driven News
HOME Canadians Should Pay NOT to be Poisoned: NDP V for Vendetta - R for Reality Canadian Bird Flu Pandemic Looming ? Shill of the Week: Stephan Harper Aspartame: The Sweetest Killer Chicken Little Terrorist of the Week: Creating Fake Terrorists Shill of the Week: Paul Martin The Number 1 Reason YOU became a Slave	U.S. experiment uses AIDS to fight AIDS Maggie Fox - Reuters November 08, 2006 An AIDS virus genetically engineered to fight other AIDS viruses worked better than expected, suppressing the virus and renewing the immune systems of a few patients, researchers reported on Monday. The study involved just five people, and such an approach needs years more study, they cautioned -- but the surprising results offer new hope both for the field of gene therapy and for treating the fatal and incurable AIDS virus. "The goal of this phase I trial was safety and feasibility and the results established that," said Dr. Carl June of the University of Pennsylvania School of Medicine, who led the study. "But the results also hint at something much more," he added. "It seemed to have a vaccine-like effect in that the immune system was better in most of the patients than when they enrolled. We are trying to study the mechanism." The AIDS virus infects close to 40 million people worldwide and has killed 25 million. A cocktail of drugs can help control infection, but there is no cure and no vaccine. The drugs cause sometimes severe side-effects in some patients and the virus can evolve resistance, so that patients have to move to new drug combinations. Gene therapy is a promising but troubled field of research based on the premise that altering genes can cure disease. It has cured only a few patients, and some have developed leukemia as a consequence. One gene therapy volunteer died in 1999. June's team tried a new gene therapy approach, first crippling the HIV virus, they report in this week's issue of the Proceedings of the National Academy of Sciences. "The virus is gutted so that it only has half the size of the original or pathogenic virus," June said in a telephone interview. ANTISENSE APPROACH The so-called envelope gene remains, and is reversed, a manipulation called antisense. The researchers then recruited five patients with HIV who were beginning to fail treatment, meaning the drugs no longer worked and the virus was beginning to damage their immune systems. June's team removed the immune cells, CD4 T-cells, that are attacked by HIV. The researchers infected the CD4 cells in the lab with their newly engineered antisense HIV virus, then infused them back onto the patients. When HIV or any other virus infects a cell, it injects its own genetic material into the cell. The cell is turned into a virus factory, sometimes pumping out thousands of copies of a virus before it explodes. After the new antisense virus was infused, newly infected cells pumped out defective virus, June said. "The virus particles that are released are, like, sterile. They are nonpathogenic," June said. This test was meant only to show that the approach was safe, and three years later, none of the patients show any ill effects. The treatment appears to have helped restore the immune systems of four of the five patients, and the virus remains partly suppressed. "We put back more (CD4 cells) than we took out. We don't know if that is why their immune system gets better, because there are more soldiers, or whether it got better because of better antiviral effects," June said. The therapy is being developed by Gaithersburg, Maryland-based VIRxSYS Corp. and the studies are partly paid for by the National Institute of Allergy and Infectious Diseases. Phase II trials are underway in HIV patients who have disease well-controlled by drugs. June said it is not yet clear if the treatment could work only in infected patients, or might even be used as a preventive vaccine some day. Read the full article here Broken Link? If the link to the original article is broken or has been altered you can view the article by clicking here. About KDR \| \| Home \| \| Weekly Features Archive	Weekly Features Archive
		What Is Wrong With Canada ? Recent 9-11 News Suppressed by the Media Aspartame: The Sweetest Killer The Number 1 Reason YOU became a Slave Knowledge Driven Look at Your Favourite Canadian Political Parties
		September October November 2006 29 30 31 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 01 02 Weekly Features 2006 2005 Read Today's Knowledge Driven News
		Counter
Copyright � 2005-6 KnowledgeDrivenRevolution.com